However, this PFS6 rate is similar to the PFS6 rate reported in a study of onapristone extended‐release monotherapy in progesterone receptor positive GCT (21.4%) in which patients received a median of 2 (range, 1–6) prior lines of chemotherapy and a median of 1 (range, 0–8) prior lines of hormonal therapy16 and had no responses by RECIST. The gene discussed is PGR; the disease is granular cell tumor.